Isaac Barchas Sells 11,048 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 11,048 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00. Following the completion of the transaction, the director owned 92,211 shares in the company, valued at approximately $2,512,749.75. This represents a 10.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The shares were sold at an average price of $26.23, for a total transaction of $1,633,892.93.
• On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The stock was sold at an average price of $26.07, for a total transaction of $263,958.75.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total value of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total value of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total value of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total value of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $26.42 on Friday. Immunome, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $28.62. The business has a 50-day simple moving average of $22.02 and a two-hundred day simple moving average of $22.20. The firm has a market cap of $3.00 billion, a price-to-earnings ratio of -10.44 and a beta of 2.08.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). As a group, research analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

Hedge Funds Weigh In On Immunome

A number of institutional investors have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Immunome during the second quarter valued at $254,000. Allworth Financial LP purchased a new position in shares of Immunome during the 2nd quarter valued at $25,000. E Fund Management Co. Ltd. bought a new position in Immunome in the 2nd quarter worth $248,000. Citizens Financial Group Inc. RI bought a new position in Immunome in the 2nd quarter worth $424,000. Finally, BlackRock Inc. purchased a new stake in Immunome in the 2nd quarter worth $186,588,000. 44.58% of the stock is owned by institutional investors.

Immunome News Summary

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a Buy rating. The new target implies substantial potential upside and helped support investor interest in IMNM, which reached a fresh 52-week high following the upgrade. Truist price target update
• Positive Sentiment: An investment thesis highlighted two potential catalysts: FDA acceptance of varegacestat’s new drug application and a PDUFA decision date in April 2027. Investors are also watching IM-1021, Immunome’s Phase 1 ROR1 antibody-drug conjugate, with initial data expected in 2026. The company believes its proprietary TOP1 inhibitor payload could offer advantages in efficacy, resistance management and bystander effects. Immunome catalysts and pipeline analysis
• Positive Sentiment: Immunome’s second-quarter business update kept attention focused on its antibody-based oncology and infectious-disease pipeline, which remains the primary driver of the company’s valuation and future growth prospects. Immunome second-quarter 2026 results
• Neutral Sentiment: Director Isaac Barchas sold shares in several transactions from August 10 through August 12, including approximately 98,712 shares for about $2.6 million. The sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of current management sentiment, although they may add short-term supply pressure. Immunome director sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the expected loss of $0.51. The earnings miss underscores the company’s ongoing cash-burn and execution risks while its pipeline remains in development.

Analyst Ratings Changes

A number of equities research analysts have commented on IMNM shares. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Barclays assumed coverage on Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Truist Financial increased their target price on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Wedbush raised their target price on Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.64.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.